A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

PHASE2CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

June 19, 2018

Study Completion Date

June 19, 2018

Conditions
Huntington's Disease
Interventions
DRUG

Laquinimod

Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

DRUG

Placebo

Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.

Trial Locations (53)

8036

Teva Investigational Site 31097, Barcelona

8041

Teva Investigational Site 31110, Barcelona

10032

Teva Investigational Site 12570, New York

10117

Teva Investigational Site 32480, Berlin

12800

Teva Investigational Site 54108, Prague

14618

Teva Investigational Site 12569, Rochester

20133

Teva Investigational Site 30098, Milan

Teva Investigational Site 30100, Milan

28034

Teva Investigational Site 31131, Madrid

33612

Teva Investigational Site 13490, Tampa

37232

Teva Investigational Site 13325, Nashville

38163

Teva Investigational Site 13489, Memphis

40139

Teva Investigational Site 30168, Bologna

41009

Teva Investigational Site 31187, Seville

44791

Teva Investigational Site 32482, Bochum

48149

Teva Investigational Site 32481, Münster

48903

Teva Investigational Site 31185, Barakaldo

52242

Teva Investigational Site 13326, Iowa City

55427

Teva Investigational Site 12571, Golden Valley

63110

Teva Investigational Site 12572, St Louis

67226

Teva Investigational Site 12568, Wichita

71013

Teva Investigational Site 30099, San Giovanni Rotondo

77030

Teva Investigational Site 12815, Houston

80113

Teva Investigational Site 12575, Englewood

80131

Teva Investigational Site 30097, Napoli

81675

Teva Investigational Site 32483, München

89081

Teva Investigational Site 32479, Ulm

90095

Teva Investigational Site 12565, Los Angeles

91054

Teva Investigational Site 32618, Erlangen

92037

Teva Investigational Site 12566, La Jolla

94143

Teva Investigational Site 12567, San Francisco

98034

Teva Investigational Site 12576, Kirkland

125367

Teva Investigational Site 50380, Moscow

420101

Teva Investigational Site 50379, Kazan'

603126

Teva Investigational Site 50381, Nyznij Novgorod

21287-0005

Teva Investigational Site 12574, Baltimore

V6T 2B5

Teva Investigational Site 11080, Vancouver

K1G 4G3

Teva Investigational Site 11118, Ottawa

M3B 2S7

Teva Investigational Site 11079, Toronto

T6G 2G3

Teva Investigational Site 11124, Edmonton

2333 ZA

Teva Investigational Site 38066, Leiden

1649-035

Teva Investigational Site 36026, Lisbon

09006

Teva Investigational Site 31186, Burgos

AB25 2ZN

Teva Investigational Site 34176, Aberdeen

B15 2SG

Teva Investigational Site 34177, Birmingham

L9 7LJ

Teva Investigational Site 34194, Liverpool

NW1 2PG

Teva Investigational Site 34179, London

SE1 9RT

Teva Investigational Site 34209, London

SW17 0QT

Teva Investigational Site 34204, London

W12 0NN

Teva Investigational Site 34203, London

M13 9WL

Teva Investigational Site 34175, Manchester

NE6 4QD

Teva Investigational Site 34215, Newcastle upon Tyne

S5 7AU

Teva Investigational Site 34216, Sheffield

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02215616 - A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod | Biotech Hunter | Biotech Hunter